Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
83 Results for "
CLKs
" in MedChemExpress (MCE) Product Catalog:
Products (83)
83 Results for "CLKs" in MCE Product Catalog:
Cat. No.: HY-RS02819
Target:
Research Areas:
CLK4 Human Pre-designed siRNA Set A contains three designed siRNAs for CLK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS16769
Target:
Research Areas:
Clk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Clk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS16964
Target:
Research Areas:
Clk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Clk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-157995
Target:
Research Areas:
Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC50 value of DYRK1A is 28 nM. For CLK2, Kd is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases .
Cat. No.: HY-159963
PfCLK3-IN-1 (Compound 4) is a covalent inhibitor for Plasmodium falciparum CLK3 (Pf CLK3) under alkaline conditions with an pEC50 of 7.1. PfCLK3-IN-1 reduces mature gametocytes in sexual stage parasites, and prevents transmission. PfCLK3-IN-1 inhibits P. falciparum Dd2-B2 clone with an IC50 of 239.5 nM .
Cat. No.: HY-168595
Target:
Research Areas:
CSNK2-IN-2 (compound 2) is an orally active CSNK2 inhibitor. CSNK2-IN-2 has an IC50 of 29 μM against CLK11. CSNK2-IN-2 has a half-life of 2.5 h and an AUC of 10,100 h × nM. CSNK2-IN-2 can be used in antiviral studies .
Cat. No.: HY-131909
CAS No.: 2226742-61-4
Target:
Research Areas:
CJ-2360 is a potent and orally active ALK inhibitor with IC50s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. CJ-2360 displays potent inhibitory activity against two clinically reported ALK mutants (C1156Y and L1196M) and a few other kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2) among the 468 kinases evaluated .
Cat. No.: HY-W409652
CAS No.: 2101206-26-0
CLK1/4-IN-2 is a selective CLK1/4 inhibitor, with an IC50 of 7 nM against CLK1 and an IC50 of 2.3 nM against CLK4. CLK1/4-IN-2 induces protein depletion in cancer cells and exhibits anticancer activity. CLK1/4-IN-2 can be used in research related to breast cancer, monocytic leukemia, bladder cancer, mammary adenocarcinoma and hepatocellular carcinoma .
Cat. No.: HY-103082R
CAS No.: 2123491-32-5
Target:
Research Areas:
CLK1-IN-1 (Standard) is the analytical standard of CLK1-IN-1 (HY-103082). This product is intended for research and analytical applications. CLK1-IN-1 is a potent and selective of Cdc2-like kinase 1 (CLK1) inhibitor, with an IC50 of 2 nM.
Cat. No.: HY-183831
CAS No.: 3034312-19-8
GPS167 is a CLK kinase inhibitor that potently and selectively inhibits recombinant human CLK1, CLK2 and CLK4. By inhibiting CLK-mediated phosphorylation of SRSF10, GPS167 upregulates the protein-binding ability of CLK1 and CLK4 with SRSF10, downregulates oncogenic BCLAF1-L and upregulates tumor-suppressive BCLAF1-S, regulates alternative splicing of genes such as MDM2 and MDM4, stabilizes p53 protein and induces DNA damage, ultimately triggering tumor cell apoptosis. GPS167 can block the epithelial-mesenchymal transition process of tumors, activate intracellular double-stranded RNA-mediated antiviral immune responses, and produce synergistic cytotoxicity when combined with microtubule-targeting drugs. GPS167 can be used in research related to various cancers including colorectal cancer .
Cat. No.: HY-RS17487
Target:
Research Areas:
Clk4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Clk4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23209
Target:
Research Areas:
Clk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Clk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23407
Target:
Research Areas:
Clk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Clk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23945
Target:
Research Areas:
Clk4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Clk4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-108709R
CAS No.: 1618658-88-0
Target:
Research Areas:
CC-671 (Standard) is the analytical standard of CC-671 (HY-108709). This product is intended for research and analytical applications. CC-671 is a dual TTK protein Kinase/CDC2-like Kinase (CLK2) inhibitor with IC50s of 0.005 and 0.006 μM for TTK and CLK2, respectively.
Cat. No.: HY-183068
AP4-43 is an orally active CLK1, CLK4, PI3K, DDR1, EGFR and NEK4 inhibitor. AP4-43 reduces growth of mammalian colorectal cancer organoids. AP4-43 improves survival in a transgenic Drosophila model of KRAS-mutant colorectal cancer. AP4-43 can be used for the research of KRAS-mutant colorectal cancer .
Cat. No.: HY-103647R
CAS No.: 443798-47-8
Target:
Research Areas:
K00546 (Standard) is the analytical standard of K00546 (HY-103647). This product is intended for research and analytical applications. K00546 is a potent CDK1 and CDK2 inhibitor with IC50s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC50s of 8.9 nM and 29.2 nM, respectively .
Cat. No.: HY-402805A
Target:
Research Areas:
DYRK2-IN-2 hydrochloride is a selective DYRK2 inhibitor with an IC50 of 40.3 nM. DYRK2-IN-2 hydrochloride shows weaker inhibitory activity against DYRK1A (IC50 = 1842 nM), DYRK1B (IC50 = 1335 nM), DYRK4 (IC50 = 1931 nM), DYRK3 (IC50 = 112 nM) and CLK (IC50 = 540-6496 nM). DYRK2-IN-2 hydrochloride inhibits the phosphorylation of Thr212 in Tau protein. DYRK2-IN-2 hydrochloride is applicable for neuronal research .
Cat. No.: HY-402805
CAS No.: 2416195-65-6
Target:
Research Areas:
DYRK2-IN-2 (Compound C17) is a selective inhibitor of DYRK2, with its IC50 value being 40.3 nM. The inhibitory activity of DYRK2-IN-2 on DYRK1A (IC50 = 1842 nM), DYRK1B (IC50 = 1335 nM), DYRK4 (IC50 = 1931 nM), DYRK3 (IC50 = 112 nM), and CLKs (IC50 = 540-6496 NM) is relatively low. DYRK2-IN-2 inhibits the phosphorylation of Tau protein at Thr212 and shows moderate cytotoxicity in HT22 cells. DYRK2-IN-2 can be used in cancer research .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
